Rizatriptan

Identification

Molecular formula

C₁₅H₁₉FN₄O₂

CAS number

144034-80-0

IUPAC name

3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidyl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one

State

Rizatriptan is typically found in a solid state at room temperature. It is formulated as tablets for oral administration.

Melting point (Celsius)

178.00

Melting point (Kelvin)

451.00

Boiling point (Celsius)

481.10

Boiling point (Kelvin)

754.20

General information

Molecular weight

269.35g/mol

Molar mass

269.3480g/mol

Density

1.4000g/cm³

Appearence

Rizatriptan is a white to off-white crystalline powder.

Comment on solubility

Solubility of 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidyl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one (C₁₅H₁₉FN₄O₂)

The solubility of complex organic compounds like 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidyl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one can be influenced by several factors. Understanding its solubility is vital for predicting its behavior in various environments. Here are key aspects regarding its solubility:

Polarity: The presence of polar functional groups may enhance solubility in polar solvents, while non-polar regions may favor solubility in non-polar solvents.
Hydrogen Bonding: As this compound contains multiple nitrogen and oxygen atoms, it is likely to engage in hydrogen bonding, possibly increasing solubility in aqueous solutions.
pH Sensitivity: The solubility of this compound could vary with pH changes, especially due to the basic and acidic nature of certain groups present in its structure.
Temperature Effects: As with many chemical substances, solubility may increase with temperature, influencing its dissolution characteristics in thermal conditions.

Potential solubility levels could be categorized as:

Highly soluble: If the compound contains functional groups that are very polar.
Moderately soluble: If there is a balance of polar and non-polar characteristics.
Poorly soluble: If the non-polar components predominate.

To summarize, the solubility of C₁₅H₁₉FN₄O₂ will largely depend on its molecular structure and environmental conditions. Carrying out empirical solubility tests and deriving from theoretical predictions will provide deeper insight into its dissolving behavior.

Interesting facts

Insights into 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidyl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one

This compound represents an interesting blend of chemical structures that logistically embody complexity and functionality within medicinal chemistry. It is an example of how diverse ring systems can be fused together to create compounds with potential pharmacological significance.

Key Features

Multi-ring Structure: The presence of a pyrimidine and a piperidine moiety in its structure contributes to its chemical diversity.
Fluorine Atom: The addition of a fluorine atom increases the lipophilicity of the compound, potentially enhancing its bioavailability and interaction with biological systems.
Benzoxazole Component: Known for its biological activity, the benzoxazole group can play a critical role in modulating various biochemical pathways.

Potential Applications

The unique structure suggests that this compound may be subjected to extensive research within the fields of:

Antidepressants: Given the piperidine structure, it may interact with neurotransmitter systems.
Anticancer Agents: The fused ring systems could provide a platform for developing new anticancer therapies.
CNS Disorders: Investigations can be aimed at understanding its effect on various central nervous system functions.

Innovative Research

Researchers are showing increased interest in multi-component synthesis methods, which could lead to more efficient production strategies for this compound. As stated by a renowned scientist, "The future of drug discovery relies on understanding the intricate dance of heterocyclic compounds." This highlights the significance of similar compounds in finding novel therapeutic agents.

In summary, 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidyl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one encapsulates the essence of innovation in chemical synthesis, with the potential of impacting various areas of healthcare through advanced drug development.

Synonyms

risperidone

106266-06-2

Risperdal

Risperidal

Rispolept

Risperin

Rispolin

Sequinan

Risperdal Consta

Risperidona

Risperidal M-Tab

Risperidonum

Apexidone

Risperdal M-Tab

Spiron

Risperidonum [Latin]

R 64 766

Belivon

C23H27FN4O2

Perseris

Psychodal

Zophrenal

RYKINDO

UZEDY

Risperidone impurity K

UNII-L6UH7ZF8HC

R 64766

R-64766

L6UH7ZF8HC

R 64,766

3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one

MFCD00274576

NSC-759895

BRN 4891881

CHEBI:8871

DTXSID8045193

R-64-766

HSDB 7580

N05AX08

RCN3028

RCN-3028

CHEMBL85

3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

R-64,766

LY-03004

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

DTXCID6025193

Risperidona [Spanish]

Risperidone [USAN:USP:INN:BAN]

106266-06-2 (free base)

Risperidonum (Latin)

NSC 759895

NCGC00015883-05

CAS-106266-06-2

RISPERIDONE (MART.)

RISPERIDONE [MART.]

RISPERIDONE (USP-RS)

RISPERIDONE [USP-RS]

3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-2-methyl-4h-pyrido(1,2-a)pyrimidin-4-one

3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidyl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one

3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

3-{2-[4-(6-FLUORO-BENZO[D]ISOXAZOL-3-YL)-PIPERIDIN-1-YL]-ETHYL}-2-METHYL-6,7,8,9-TETRAHYDRO-PYRIDO[1,2-A]PYRIMIDIN-4-ONE

4H-Pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-2-methyl-

RISPERIDONE (EP IMPURITY)

RISPERIDONE [EP IMPURITY]

RISPERIDONE (EP MONOGRAPH)

RISPERIDONE (USP IMPURITY)

RISPERIDONE [EP MONOGRAPH]

RISPERIDONE [USP IMPURITY]

RISPERIDONE (USP MONOGRAPH)

RISPERIDONE [USP MONOGRAPH]

Risperidone (USAN:USP:INN:BAN)

Risperdal (TN)

3-[2-[4-(6-fluoranyl-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one

3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

3-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino]ethyl}-6,7,8,9-tetrahydro-2-methylpyrido[1,2-a]pyrimidin-4-one

3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one

4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-

SMR000466323

SR-01000075399

Relday

Rispen

Okedi

Risperidone-ISM

Risperidone???

Risperidone M-tab

3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido(1,2-a)pyrimidin-4-one

3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

Risperidone; 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- (9CI); 1,2-Benzisoxazole, 4H-pyrido[1,2-a]pyrimidin-4-one deriv.; R 64766; Risperdal; Spiron

RISVAN

3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one

KS-1106

PERSERIS KIT

Risperidone (Standard)

Risperidone (Risperdal)

Lopac-R-118

RISPERIDONE [MI]

Prestwick0_001029

Prestwick1_001029

RISPERIDONE [INN]

RISPERIDONE [JAN]

R-118

RISPERIDONE [HSDB]

RISPERIDONE [USAN]

GTPL96

RISPERIDONE [VANDF]

Risperidone(R 64 766)

SCHEMBL27911

RISPERIDONE [WHO-DD]

MLS000759429

MLS001165758

MLS001424081

US8802672, Risperidone

BIDD:GT0262

R 62 766

SPBio_003078

Risperidone;Apexidone;Psychodal

Risperidone (JP17/USP/INN)

Risperidone - Bio-X trade mark

Risperidone, 1mg/ml in Methanol

RISPERIDONE [ORANGE BOOK]

HMS1571M19

HMS2051H07

HMS2089C22

HMS2098M19

HMS2233O11

HMS3373M18

HMS3393H07

HMS3657G13

HMS3715M19

HMS3753M15

HMS3887G15

Pharmakon1600-01506038

Rykindoextended-release microspheres

BCP08161

Risperidone 1.0 mg/ml in Methanol

Tox21_110253

BDBM50001885

CP-018

HB1740

HY-11018R

NSC759895

NSC786035

NSC801188

s1615

STK646402

AKOS005577302

Tox21_110253_1

AC-1306

CCG-100930

CS-1619

DB00734

FR27737

LY03004

NC00180

NSC-786035

NSC-801188

PB26023

Risperidone, >=98% (HPLC), powder

NCGC00015883-01

NCGC00015883-02

NCGC00015883-03

NCGC00015883-04

NCGC00015883-06

NCGC00015883-07

NCGC00015883-08

NCGC00015883-11

NCGC00094352-01

NCGC00094352-02

NCGC00094352-03

NCGC00179257-01

1026102-43-1

3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one

3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one

4H-Pyrido(1,2-a)pyrimidin-4-one, 6,7,8,9-tetrahydro-3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-2-methyl-

BR164349

HY-11018

AB00514010

EU-0101074

NS00000033

R0087

SW197348-4

D00426

EN300-117259

AB00514010-09

AB00514010-11

AB00514010-12

AB00514010_13

AB00514010_14

L000510

Q412443

SR-01000075399-2

SR-01000075399-8

BRD-K53857191-001-04-5

BRD-K53857191-001-10-2

BRD-K53857191-001-21-9

BRD-K53857191-001-22-7

Z1501480428

Risperidone, British Pharmacopoeia (BP) Reference Standard

Risperidone, European Pharmacopoeia (EP) Reference Standard

Risperidone, United States Pharmacopeia (USP) Reference Standard

Risperidone, Pharmaceutical Secondary Standard; Certified Reference Material

Risperidone for system suitability, European Pharmacopoeia (EP) Reference Standard

(risperidone)3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one

2-(2-(4-(benzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-7,8,9,9a-tetrahydro-1H-pyrido[1,2-a]pyrimidin-4(6H)-one

2-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-6,7,8,8a-tetrahydro-5H-naphthalen-1-one

3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)- 6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one

3-(2-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one

3-[2-[4(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

3-[2-[4(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl4H-pyrido[1,2-a]pyrimidin-4-one

3-[2-[4-(6 fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

3-[2-[4-(6-fluoro- 1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl4H-pyrido[1,2-a]pyrimidin-4-one

3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidiny]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-A]pyrimidin-4-one

3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-me thyl-4H-pyrido[1,2-a]pyrimidin-4-one

3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[2,1-b]pyrimidin-4-one

3-[2-4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one;Apexidone;Ps ychodal

3-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl}- 6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimid-in-4-one

3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one (Resperidone)

3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one (risperidone)

3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one(risperidone)

3-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

4H-Pyrido(1,2-a)pyrimidin-4-one, 6,7,8,9-tetrahydro-3-(2-(4- (6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-2- methyl-

4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benz-isoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-

5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-methyl-1,3-dihydro-indol-2-one(Norastemizole)

Solubility of 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidyl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one (C15H19FN4O2)

Insights into 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidyl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one

Key Features

Potential Applications

Innovative Research

Solubility of 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidyl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one (C₁₅H₁₉FN₄O₂)